Discover which therapies are expected to grab the HER2-low cancers market share @ HER2-low Cancers Market Report The HER2-low ...

Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test becomes the only FDA approved companion diagnostic indicated to aid assessment of HER2 low-metastatic breast cancer ...

the monoclonal antibody targeting HER2 (also referred to as HER2/neu and ERBB2) evens the playing field for breast cancer patients overexpressing HER2, whose tumors are typically more aggressive.

Sevabertinib shows promise for advanced NSCLC with HER2 mutations, achieving a 72.1% objective response rate in the SOHO-01 trial. Patients with HER2 YVMA insertions exhibited a 90% objective response ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

Trastuzumab deruxtecan plus pertuzumab significantly extends PFS compared to THP in HER2-positive metastatic breast cancer. The combination demonstrated a 44% lower risk of disease progression or ...

"DESTINY-Gastric04 showed statistically significant and clinically meaningful improvement in overall survival with second-line T-DXd over ramucirumab-paclitaxel in patients with advanced HER2 ...